Role of cytochrome P450 genotype in the steps toward personalized drug therapy

References

• US Food and Drug AdministrationTable of pharmacogenomic biomarkers in drug labels [web page on the Internet]Silver Spring, MDUS Food and Drug Administration2011 [updated September 27]. Available from: http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm083378.htm. Accessed September 29, 2011
   Google Scholar
• MoSLZhouZWYangLPWeiMQZhouSFNew insights into the structural features and functional relevance of human cytochrome P450 2C9. Part ICurr Drug Metab200910101075112620167001
   PubMed Web of Science ®Google Scholar
• SimSCCYP2CP allele nomenclature. Home page of the Human Cytochrome P450 (CYP) Allele Nomenclature Committee [website on the Internet] Human Cytochrome P450 (CYP) Allele Nomenclature Committee; 2011 [updated May 2]. Available from: http://www.cypalleles.ki.se/cyp2c9.htm. Accessed September 28, 2011.
   Google Scholar
• GageBFEbyCJohnsonJAUse of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarinClin Pharmacol Ther200884332633118305455
   PubMed Web of Science ®Google Scholar
• CavallariLHLangaeeTYMomaryKMGenetic and clinical predictors of warfarin dose requirements in African AmericansClin Pharmacol Ther201087445946420072124
   PubMed Web of Science ®Google Scholar
• TakahashiHWilkinsonGRNutescuEADifferent contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-AmericansPharmacogenet Genomics200616210111016424822
   PubMed Web of Science ®Google Scholar
• RettieAEWienkersLCGonzalezFJTragerWFKorzekwaKRImpaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9Pharmacogenetics19944139428004131
   PubMedGoogle Scholar
• LeeCRGoldsteinJAPieperJACytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human dataPharmacogenetics200212325126311927841
   PubMedGoogle Scholar
• Sullivan-KloseTHGhanayemBIBellDAThe role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphismPharmacogenetics1996643413498873220
   PubMedGoogle Scholar
• WeiLLocusonCWTracyTSPolymorphic variants of CYP2C9: mechanisms involved in reduced catalytic activityMol Pharmacol20077251280128817686967
   PubMed Web of Science ®Google Scholar
• DickmannLJRettieAEKnellerMBIdentification and functional characterization of a new CYP2C9 variant (CYP2C9*5) expressed among African AmericansMol Pharmacol200160238238711455026
   PubMed Web of Science ®Google Scholar
• AllabiACGalaJLHorsmansYCYP2C9, CYP2C19, ABCB1 (MDR1) genetic polymorphisms and phenytoin metabolism in a Black Beninese populationPharmacogenet Genomics2005151177978616220110
   PubMed Web of Science ®Google Scholar
• BlaisdellJJorge-NebertLFCoulterSDiscovery of new potentially defective alleles of human CYP2C9Pharmacogenetics200414852753715284535
   PubMedGoogle Scholar
• AllabiACGalaJLHorsmansYFunctional impact of CYP2C95, CYP2C96, CYP2C98, and CYP2C911 in vivo among black AfricansClin Pharmacol Ther200476211311815289788
   PubMed Web of Science ®Google Scholar
• TakanashiKTainakaHKobayashiKYasumoriTHosakawaMChibaKCYP2C9 Ile359 and Leu359 variants: enzyme kinetic study with seven substratesPharmacogenetics20001029510410761997
   PubMedGoogle Scholar
• AnsellJHirshJHylekEPharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)Chest20081336 SupplS160S198
   PubMed Web of Science ®Google Scholar
• HylekEMGoASChangYEffect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillationN Engl J Med2003349111019102612968085
   PubMed Web of Science ®Google Scholar
• KearonCGinsbergJSKovacsMJComparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolismN Engl J Med2003349763163912917299
   PubMed Web of Science ®Google Scholar
• HylekEMEvans-MolinaCSheaCHenaultLEReganSMajor hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillationCirculation2007115212689269617515465
   PubMed Web of Science ®Google Scholar
• WadeliusMChenLYLindhJDThe largest prospective warfarin-treated cohort supports genetic forecastingBlood2009113478479218574025
   PubMed Web of Science ®Google Scholar
• ScordoMGPengoVSpinaEDahlMLGusellaMPadriniRInfluence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearanceClin Pharmacol Ther200272670271012496751
   PubMed Web of Science ®Google Scholar
• TakahashiHKashimaTNomizoYMetabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypesClin Pharmacol Ther19986355195289630825
   PubMed Web of Science ®Google Scholar
• AithalGPDayCPKestevenPJDalyAKAssociation of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complicationsLancet1999353915471771910073515
   PubMed Web of Science ®Google Scholar
• HigashiMKVeenstraDLKondoLMAssociation between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapyJAMA2002287131690169811926893
   PubMed Web of Science ®Google Scholar
• LimdiNABeasleyTMCrowleyMRVKORC1 polymorphisms, haplotypes and haplotype groups on warfarin dose among African-Americans and European-AmericansPharmacogenomics20089101445145818855533
   PubMed Web of Science ®Google Scholar
• MargaglioneMColaizzoDD’AndreaGGenetic modulation of oral anticoagulation with warfarinThromb Haemost200084577577811127854
   PubMed Web of Science ®Google Scholar
• TaubeJHalsallDBaglinTInfluence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatmentBlood20009651816181910961881
   PubMed Web of Science ®Google Scholar
• KleinTEAltmanRBErikssonNEstimation of the warfarin dose with clinical and pharmacogenetic dataN Engl J Med2009360875376419228618
   PubMed Web of Science ®Google Scholar
• LimdiNAWadeliusMCavallariLWarfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groupsBlood2010115183827383420203262
   PubMed Web of Science ®Google Scholar
• CooperGMJohnsonJALangaeeTYA genome-wide scan for common genetic variants with a large influence on warfarin maintenance doseBlood200811241022102718535201
   PubMed Web of Science ®Google Scholar
• TakeuchiFMcGinnisRBourgeoisSA genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dosePLoS Genet200953e1000433 Epub March 20, 200919300499
   PubMed Web of Science ®Google Scholar
• PereraMAGamazonECavallariLHThe missing association: sequencing-based discovery of novel SNPs in VKORC1 and CYP2C9 that affect warfarin dose in African AmericansClin Pharmacol Ther201189340841521270790
   PubMed Web of Science ®Google Scholar
• LimdiNAMcGwinGGoldsteinJAInfluence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarinClin Pharmacol Ther200883231232117653141
   PubMed Web of Science ®Google Scholar
• SandersonSEmeryJHigginsJCYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: a HuGEnet systematic review and meta-analysisGenet Med2005729710415714076
   PubMed Web of Science ®Google Scholar
• KoukouritakiSBManroJRMarshSADevelopmental expression of human hepatic CYP2C9 and CYP2C19J Pharmacol Exp Ther2004308396597414634042
   PubMed Web of Science ®Google Scholar
• Nowak-GöttlUDietrichKSchaffranekDIn pediatric patients, age has more impact on dosing of vitamin K antagonists than VKORC1 or CYP2C9 genotypesBlood2010116266101610520833980
   PubMed Web of Science ®Google Scholar
• CaracoYBlotnickSMuszkatMCYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled studyClin Pharmacol Ther200883346047017851566
   PubMed Web of Science ®Google Scholar
• EpsteinRSMoyerTPAubertREWarfarin genotyping reduces hospitalization rates results from the MM-WES (Medco-Mayo Warfarin Effectiveness study)J Am Coll Cardiol201055252804281220381283
   PubMed Web of Science ®Google Scholar
• HuangSWChenHSWangXQValidation of VKORC1 and CYP2C9 genotypes on interindividual warfarin maintenance dose: a prospective study in Chinese patientsPharmacogenet Genomics200919322623419177029
   PubMed Web of Science ®Google Scholar
• AndersonJLHorneBDStevensSMRandomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulationCirculation2007116222563257017989110
   PubMed Web of Science ®Google Scholar
• BurmesterJKBergRLYaleSHA randomized controlled trial of genotype-based Coumadin initiationGenet Med201113650951821423021
   PubMed Web of Science ®Google Scholar
• FrenchBJooJGellerNLStatistical design of personalized medicine interventions: the Clarification of Optimal Anticoagulation through Genetics (COAG) trialTrials20101110821083927
   PubMed Web of Science ®Google Scholar
• Coumadin® (warfarin sodium) [package insert]Princeton, NJBristol-Myers Squibb2010
   Google Scholar
• ShinJCaoDComparison of warfarin pharmacogenetic dosing algorithms in a racially diverse large cohortPharmacogenomics201112112513421174627
   PubMed Web of Science ®Google Scholar
• WuAHWangPSmithADosing algorithm for warfarin using CYP2C9 and VKORC1 genotyping from a multi-ethnic population: comparison with other equationsPharmacogenomics20089216917818370846
   PubMed Web of Science ®Google Scholar
• SconceEAKhanTIWynneHAThe impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimenBlood200510672329233315947090
   PubMed Web of Science ®Google Scholar
• KüpferADesmondPVSchenkerSFamily study of a genetically determined deficiency of mephenytoin hydroxylation in man [letter]Pharmacologist197921173
   Google Scholar
• GoldsteinJAFalettoMBRomkes-SparksMEvidence that CYP2C19 is the major (S)-mephenytoin 4′-hydroxylase in humansBiochemistry1994337174317528110777
   PubMed Web of Science ®Google Scholar
• WedlundPJAslanianWSMcAllisterCBWilkinsonGRBranchRAMephenytoin hydroxylation deficiency in Caucasians: frequency of a new oxidative drug metabolism polymorphismClin Pharmacol Ther19843667737806499356
   PubMed Web of Science ®Google Scholar
• KüpferAPreisigRPharmacogenetics of mephenytoin: a new drug hydroxylation polymorphism in manEur J Clin Pharmacol19842667537596489416
   PubMed Web of Science ®Google Scholar
• SimSCCYP2C9 allele nomenclature. Home page of the Human Cytochrome P450 (CYP) Allele Nomenclature Committee [website on the Internet] Human Cytochrome P450 (CYP) Allele Nomenclature Committee; 2011 [updated May 2]. Available from: http://www.cypalleles.ki.se/cyp2c19.htm. Accessed September 29, 2011
   Google Scholar
• de MoraisSWilkinsonGRBlaisdellJNakamuraKMeyerUAGoldsteinJAThe major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humansJ Biol Chem19942692215419154228195181
   PubMed Web of Science ®Google Scholar
• GoldsteinJAIshizakiTChibaKFrequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populationsPharmacogenetics19977159649110363
   PubMedGoogle Scholar
• WedlundPJThe CYP2C19 enzyme polymorphismPharmacology200061317418310971203
   PubMed Web of Science ®Google Scholar
• DestaZZhaoXShinJGFlockhartDAClinical significance of the cytochrome P450 2C19 genetic polymorphismClin Pharmacokinet2002411291395812222994
   PubMed Web of Science ®Google Scholar
• SimSCRisingerCDahlMLA common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressantsClin Pharmacol Ther200679110311316413245
   PubMed Web of Science ®Google Scholar
• MomaryKMDorschMPFactors associated with clopidogrel nonresponsivenessFuture Cardiol20106219521020230261
   PubMedGoogle Scholar
• SibbingDKochWGebhardDCytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placementCirculation2010121451251820083681
   PubMed Web of Science ®Google Scholar
• PatronoCBaigentCHirshJRothGAmerican College of Chest PhysiciansAntiplatelet drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)Chest20081336 SupplS199S233
   PubMed Web of Science ®Google Scholar
• ChenZMJiangLXChenYPAddition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trialLancet200536694971607162116271642
   PubMed Web of Science ®Google Scholar
• YusufSZhaoFMehtaSREffects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevationN Engl J Med2001345749450211519503
   PubMed Web of Science ®Google Scholar
• SteinhublSRBergerPBMannJT3rdEarly and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trialJAMA2002288192411242012435254
   PubMed Web of Science ®Google Scholar
• CombescureCFontanaPMalloukNClinical implications of clopidogrel non-response in cardiovascular patients: a systematic review and meta-analysisJ Thromb Haemost20108592393320156305
   PubMed Web of Science ®Google Scholar
• BonelloLTantryUSMarcucciRConsensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphateJ Am Coll Cardiol2010561291993320828644
   PubMed Web of Science ®Google Scholar
• UmemuraKFurutaTKondoKThe common gene variants of CYP2C19 affect pharmacokinetics and pharmacodynamics in an active metabolite of clopidogrel in healthy subjectsJ Thromb Haemost2008681439144118532997
   PubMed Web of Science ®Google Scholar
• VarenhorstCJamesSErlingeDGenetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery diseaseEur Heart J200930141744175219429918
   PubMed Web of Science ®Google Scholar
• BrandtJTCloseSLIturriaSJCommon polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrelJ Thromb Haemost20075122429243617900275
   PubMed Web of Science ®Google Scholar
• MegaJLCloseSLWiviottSDCytochrome p-450 polymorphisms and response to clopidogrelN Engl J Med2009360435436219106084
   PubMed Web of Science ®Google Scholar
• TrenkDHochholzerWFrommMFCytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stentsJ Am Coll Cardiol200851201925193418482659
   PubMed Web of Science ®Google Scholar
• ColletJPHulotJSPenaACytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort studyLancet2009373966030931719108880
   PubMed Web of Science ®Google Scholar
• GiustiBGoriAMMarcucciRRelation of cytochrome P450 2C19 loss-of-function polymorphism to occurrence of drug-eluting coronary stent thrombosisAm J Cardiol2009103680681119268736
   PubMed Web of Science ®Google Scholar
• ShuldinerARO’ConnellJRBlidenKPAssociation of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapyJAMA2009302884985719706858
   PubMed Web of Science ®Google Scholar
• SibbingDStegherrJLatzWCytochrome P450 2C19 loss- of-function polymorphism and stent thrombosis following percutaneous coronary interventionEur Heart J200930891692219193675
   PubMed Web of Science ®Google Scholar
• SimonTVerstuyftCMary-KrauseMGenetic determinants of response to clopidogrel and cardiovascular eventsN Engl J Med2009360436337519106083
   PubMed Web of Science ®Google Scholar
• HarmszeAMvan WerkumJWTen BergJMCYP2C19*2 and CYP2C9*3 alleles are associated with stent thrombosis: a case-control studyEur Heart J201031243046305320833683
   PubMed Web of Science ®Google Scholar
• MalekLAPrzyluskiJSpiewakMCytochrome P450 2C19 polymorphism, suboptimal reperfusion and all-cause mortality in patients with acute myocardial infarctionCardiology20101172818720924183
   PubMed Web of Science ®Google Scholar
• MegaJLSimonTColletJPReduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysisJAMA2010304261821183020978260
   PubMed Web of Science ®Google Scholar
• ParéGMehtaSRYusufSEffects of CYP2C19 genotype on outcomes of clopidogrel treatmentN Engl J Med2010363181704171420979470
   PubMed Web of Science ®Google Scholar
• ConnollySJPogueJHartRGEffect of clopidogrel added to aspirin in patients with atrial fibrillationN Engl J Med20093602066207819336502
   PubMed Web of Science ®Google Scholar
• US Food and Drug AdministrationFDA announces new boxed warning on Plavix: alerts patients, health care professionals to potential for reduced effectiveness [press release]Silver Spring, MDUS Food and Drug Administration 2010 [March 12]. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm204253.htm. Accessed July 27, 2011
   Google Scholar
• ScottSASangkuhlKGardnerEEClinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450–452C19 (CYP2C19) Genotype and Clopidogrel TherapyClin Pharmacol Ther201190232833221716271
   PubMed Web of Science ®Google Scholar
• MegaJLCloseSLWiviottSDCytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomesCirculation2009119192553256019414633
   PubMed Web of Science ®Google Scholar
• KellyRPCloseSLFaridNAPharmacokinetics and Pharmacodynamics Following Maintenance Doses of Prasugrel and Clopidogrel in Chinese Carriers of CYP2C19 VariantsBr J Clin Pharmacol201110.1111/j.1365-2125.2011.04049.x [Epub ahead of print.]
   Web of Science ®Google Scholar
• WallentinLJamesSStoreyRFEffect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trialLancet201037697491320132820801498
   PubMed Web of Science ®Google Scholar
• KimISJeongYHParkYPlatelet Inhibition by Adjunctive Cilostazol Versus High Maintenance-Dose Clopidogrel in Patients With Acute Myocardial Infarction According to Cytochrome P450 2C19 GenotypeJACC Cardiovasc Interv20114438139121511217
   PubMed Web of Science ®Google Scholar
• HwangSJJeongYHKimISCytochrome 2C19 polymorphism and response to adjunctive cilostazol versus high maintenance-dose clopidogrel in patients undergoing percutaneous coronary interventionCirc Cardiovasc Interv20103545045920823393
   PubMed Web of Science ®Google Scholar
• ParkKWParkJJLeeSPCilostazol attenuates on-treatment platelet reactivity in patients with CYP2C19 loss of function alleles receiving dual antiplatelet therapy: a genetic substudy of the CILON-T randomised controlled trialHeart201197864164721345843
   PubMed Web of Science ®Google Scholar
• PriceMJBergerPBTeirsteinPSStandard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trialJAMA2011305111097110521406646
   PubMed Web of Science ®Google Scholar
• SaitohTFukushimaYOtsukaHEffects of rabeprazole, lansoprazole and omeprazole on intragastric pH in CYP2C19 extensive metabolizersAliment Pharmacol Ther200216101811181712269976
   PubMed Web of Science ®Google Scholar
• ShiraiNFurutaTXiaoFComparison of lansoprazole and famotidine for gastric acid inhibition during the daytime and night-time in different CYP2C19 genotype groupsAliment Pharmacol Ther200216483784611929404
   PubMed Web of Science ®Google Scholar
• ShiraiNFurutaTMoriyamaYEffects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pHAliment Pharmacol Ther200115121929193711736724
   PubMed Web of Science ®Google Scholar
• FurutaTOhashiKKamataTEffect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcerAnn Intern Med199812912102710309867757
   PubMed Web of Science ®Google Scholar
• FurutaTShiraiNTakashimaMEffects of genotypic differences in CYP2C19 status on cure rates for Helicobacter pylori infection by dual therapy with rabeprazole plus amoxicillinPharmacogenetics200111434134811434512
   PubMedGoogle Scholar
• FurutaTShiraiNTakashimaMEffect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycinClin Pharmacol Ther200169315816811240980
   PubMed Web of Science ®Google Scholar
• TanigawaraYAoyamaNKitaTCYP2C19 genotype-related efficacy of omeprazole for the treatment of infection caused by Helicobacter pyloriClin Pharmacol Ther199966552853410579481
   PubMed Web of Science ®Google Scholar
• FurutaTShiraiNWatanabeFEffect of cytochrome P4502C19 genotypic differences on cure rates for gastroesophageal reflux disease by lansoprazoleClin Pharmacol Ther200272445346012386647
   PubMed Web of Science ®Google Scholar
• KearnsGLLeederJSGaedigkAImpact of the CYP2C19*17 allele on the pharmacokinetics of omeprazole and pantoprazole in children: evidence for a differential effectDrug Metab Dispos201038689489720223877
   PubMed Web of Science ®Google Scholar
• SugimotoMFurutaTShiraiNDifferent dosage regimens of rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotype statusClin Pharmacol Ther200476429030115470328
   PubMed Web of Science ®Google Scholar
• SaitohACapparelliEAweekaFCYP2C19 genetic variants affect nelfinavir pharmacokinetics and virologic response in HIV-1-infected children receiving highly active antiretroviral therapyJ Acquir Immune Defic Syndr201054328528919890215
   PubMed Web of Science ®Google Scholar
• HaasDWSmeatonLMShaferRWPharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and/or Nelfinavir: an Adult Aids Clinical Trials Group StudyJ Infect Dis2005192111931194216267764
   PubMed Web of Science ®Google Scholar
• MahgoubAIdleJRDringLGLancasterRSmithRLPolymorphic hydroxylation of Debrisoquine in manLancet19772803858458671400
   PubMed Web of Science ®Google Scholar
• EichelbaumMSpannbruckerNSteinckeBDenglerHJDefective N-oxidation of sparteine in man: a new pharmacogenetic defectEur J Clin Pharmacol1979163183187499318
   PubMed Web of Science ®Google Scholar
• BradfordLDCYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendantsPharmacogenomics20023222924311972444
   PubMed Web of Science ®Google Scholar
• JohanssonILundqvistEBertilssonLDahlMLSjöqvistFIngelman-SundbergMInherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquineProc Natl Acad Sci U S A1993902411825118297903454
   PubMed Web of Science ®Google Scholar
• Ingelman-SundbergMGenetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversityPharmacogenomics J20055161315492763
   PubMed Web of Science ®Google Scholar
• EckhardtKLiSAmmonSSame incidence of adverse drug events after codeine administration irrespective of the genetically determined differences in morphine formationPain1998761–227339696456
   PubMed Web of Science ®Google Scholar
• SindrupSHBrøsenKBjerringPCodeine increases pain thresholds to copper vapor laser stimuli in extensive but not poor metabolizers of sparteineClin Pharmacol Ther19904866866932249379
   PubMed Web of Science ®Google Scholar
• StamerUMLehnenKHöthkerFImpact of CYP2D6 genotype on postoperative tramadol analgesiaPain20031051–223123814499440
   PubMed Web of Science ®Google Scholar
• WangGZhangHHeFFangXEffect of the CYP2D6*10 C188T polymorphism on postoperative tramadol analgesia in a Chinese populationEur J Clin Pharmacol2006621192793116960721
   PubMed Web of Science ®Google Scholar
• KirchheinerJKeulenJTBauerSRootsIBrockmöllerJEffects of the CYP2D6 gene duplication on the pharmacokinetics and pharmacodynamics of tramadolJ Clin Psychopharmacol2008281788318204346
   PubMed Web of Science ®Google Scholar
• GascheYDaaliYFathiMCodeine intoxication associated with ultrarapid CYP2D6 metabolismN Engl J Med2004351272827283115625333
   PubMed Web of Science ®Google Scholar
• DalénPFrengellCDahlMLSjöqvistFQuick onset of severe abdominal pain after codeine in an ultrarapid metabolizer of debrisoquineTher Drug Monit19971955435449357099
   PubMed Web of Science ®Google Scholar
• MadadiPRossCJHaydenMRPharmacogenetics of neonatal opioid toxicity following maternal use of codeine during breastfeeding: a case-control studyClin Pharmacol Ther2009851313518719619
   PubMed Web of Science ®Google Scholar
• Kwadijk-de GijselSBijlMJVisserLEVariation in the CYP2D6 gene is associated with a lower serum sodium concentration in patients on antidepressantsBr J Clin Pharmacol200968222122519694742
   PubMed Web of Science ®Google Scholar
• BijlMJVisserLEHofmanAInfluence of the CYP2D6*4 polymor phism on dose, switching and discontinuation of antidepressantsBr J Clin Pharmacol200865455856418070221
   PubMed Web of Science ®Google Scholar
• LeeSYSohnKMRyuJYYoonYRShinJGKimJWSequence-based CYP2D6 genotyping in the Korean populationTher Drug Monit200628338238716778723
   PubMed Web of Science ®Google Scholar
• BertilssonLAberg-WistedtAGustafssonLLNordinCExtremely rapid hydroxylation of debrisoquine: a case report with implication for treatment with nortriptyline and other tricyclic antidepressantsTher Drug Monit1985744784804082245
   PubMed Web of Science ®Google Scholar
• BertilssonLDahlMLSjöqvistFMolecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquineLancet19933418836638093319
   PubMed Web of Science ®Google Scholar
• ThakurMGrossmanIMcCroryDCReview of evidence for genetic testing for CYP450 polymorphisms in management of patients with nonpsychotic depression with selective serotonin reuptake inhibitorsGenet Med200791282683518091432
   PubMed Web of Science ®Google Scholar
• CharlierCBrolyFLhermitteMPintoEAnsseauMPlomteuxGPolymorphisms in the CYP2D6 gene: association with plasma concentrations of fluoxetine and paroxetineTher Drug Monit200325673874214639062
   PubMed Web of Science ®Google Scholar
• FleemanNDundarYDicksonRCytochrome P450 testing for prescribing antipsychotics in adults with schizophrenia: systematic review and meta-analysesPharmacogenomics J201011111420877299
   PubMed Web of Science ®Google Scholar
• DahlMLCytochrome p450 phenotyping/genotyping in patients receiving antipsychotics: useful aid to prescribing?Clin Pharmacokinet200241745347012083975
   PubMed Web of Science ®Google Scholar
• SuzukiTMiharaKNakamuraAEffects of the CYP2D6*10 allele on the steady-state plasma concentrations of aripiprazole and its active metabolite, dehydroaripiprazole, in Japanese patients with schizophreniaTher Drug Monit2011331212421157400
   PubMed Web of Science ®Google Scholar
• LlerenaABereczRde la RubiaADoradoPQTc interval lengthening is related to CYP2D6 hydroxylation capacity and plasma concentration of thioridazine in patientsJ Psychopharmacol200216436136412503836
   PubMed Web of Science ®Google Scholar
• RauTWuttkeHMichelsLMImpact of the CYP2D6 genotype on the clinical effects of metoprolol: a prospective longitudinal studyClin Pharmacol Ther200985326927219037197
   PubMed Web of Science ®Google Scholar
• TerraSGPaulyDFLeeCRbeta-Adrenergic receptor polymorphisms and responses during titration of metoprolol controlled release/extended release in heart failureClin Pharmacol Ther200577312713715735607
   PubMed Web of Science ®Google Scholar
• JohnsonJAZinehIPuckettBJMcGorraySPYarandiHNPaulyDFBeta 1-adrenergic receptor polymorphisms and antihypertensive response to metoprololClin Pharmacol Ther2003741445212844134
   PubMed Web of Science ®Google Scholar
• TerraSGHamiltonKKPaulyDFBeta1-adrenergic receptor polymorphisms and left ventricular remodeling changes in response to beta-blocker therapyPharmacogenet Genomics200515422723415864115
   PubMedGoogle Scholar
• MürdterTESchrothWBacchus-GerybadzeLActivity levels of tamoxifen metabolites at the estrogen receptor and the impact of genetic polymorphisms of phase I and II enzymes on their concentration levels in plasmaClin Pharmacol Ther201189570871721451508
   PubMed Web of Science ®Google Scholar
• MadlenskyLNatarajanLTchuSTamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomesClin Pharmacol Ther201189571872521430657
   PubMed Web of Science ®Google Scholar
• SchrothWHamannUFaschingPACYP2D6 polymorphisms as predictors of outcome in breast cancer patients treated with tamoxifen: expanded polymorphism coverage improves risk stratificationClin Cancer Res201016174468447720515869
   PubMed Web of Science ®Google Scholar
• GoetzMPKnoxSKSumanVJThe impact of cytochrome P4502D6 metabolism in women receiving adjuvant tamoxifenBreast Cancer Res Treat2007101111312117115111
   PubMed Web of Science ®Google Scholar
• SchrothWAntoniadouLFritzPBreast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypesJ Clin Oncol200725335187519318024866
   PubMed Web of Science ®Google Scholar
• LimHSJu LeeHSeok LeeKSook LeeEJangIJRoJClinical implications of CYP2D6 genotypes predictive of tamoxifen pharmacokinetics in metastatic breast cancerJ Clin Oncol200725253837384517761971
   PubMed Web of Science ®Google Scholar
• NowellSAAhnJRaeJMAssociation of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patientsBreast Cancer Res Treat200591324925815952058
   PubMed Web of Science ®Google Scholar
• WegmanPVainikkaLStålOGenotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patientsBreast Cancer Res200573R284R29015987423
   PubMed Web of Science ®Google Scholar
• LashTLLienEASørensenHTHamilton-DutoitSGenotype-guided tamoxifen therapy: time to pause for reflection?Lancet Oncol200910882583319647203
   PubMed Web of Science ®Google Scholar
• YuKDHuangAJShaoZMTailoring adjuvant endocrine therapy for postmenopausal breast cancer: a CYP2D6 multiple-genotype-based modeling analysis and validationPLoS One2010512e1564921187922
   PubMed Web of Science ®Google Scholar
• HughesSVanderbilt now also routinely gene testing for clopidogrel metabolizer statusTheHeart.Org[website on the Internet]MontrealTheHeart.Org2010 Available from: http://www.theheart.org/article/1139495.do. Accessed August 11, 2011
   Google Scholar
• RellingMVAltmanRBGoetzMPEvansWEClinical implementation of pharmacogenomics: overcoming genetic exceptionalismLancet Oncol201011650750920413348
   PubMed Web of Science ®Google Scholar
• SimSCCYP2D6 allele nomenclature. Home page of the Human Cytochrome P450 (CYP) Allele Nomenclature Committee [website on the Internet] Human Cytochrome P450 (CYP) Allele Nomenclature Committee; 2011 [updated September 16]. Available from: http://www.cypalleles.ki.se/cyp2d6.htm. Accessed September 29, 2011
   Google Scholar
• CaiWMNikoloffDMPanRMCYP2D6 genetic variation in healthy adults and psychiatric African-American subjects: implications for clinical practice and genetic testingPharmacogenomics J2006634335016550211
   PubMed Web of Science ®Google Scholar
• SachseCBrockmollerJBauerSRootsICytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequencesAm J Hum Genet1997602842959012401
   PubMed Web of Science ®Google Scholar